Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

251
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
251
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

514
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
514
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

269
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
269
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

4.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
4.0K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.4K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

3.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.2K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Structural basis of insulin receptor antagonism by bivalent site 1-site 2 ligands S961 and Ins-AC-S2.

Nature communications·2026
Same author

Synthesis of Insulin-desB30 Analogs via an Enzymatically Removable N-Terminal Solubilizing Tag.

Organic letters·2025
Same author

Structural basis of insulin receptor antagonism by bivalent site 1-site 2 ligands.

bioRxiv : the preprint server for biology·2025
Same author

Modulation of insulin receptor activation through controlled folding of peptide ligands.

Organic & biomolecular chemistry·2025
Same author

Prohormone cleavage prediction uncovers a non-incretin anti-obesity peptide.

Nature·2025
Same author

Insulin Stabilization Designs for Enhanced Therapeutic Efficacy and Accessibility.

Accounts of chemical research·2024

関連する実験動画

Updated: Sep 7, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.0K

性能を改善するためにインスリンを修正する

Nai-Pin Lin1, Danny Hung-Chieh Chou1

  • 1Stanford University, School of Medicine, Palo Alto, CA, USA.

Science (New York, N.Y.)
|June 16, 2022
PubMed
まとめ
この要約は機械生成です。

インスリンプラットフォームの精密な修正は,薬の機能性を高めることができます. この進歩により 糖尿病の治療効果が向上する可能性があります

さらに関連する動画

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.7K
Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion
08:22

Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion

Published on: March 20, 2017

8.8K

関連する実験動画

Last Updated: Sep 7, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.0K
An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.7K
Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion
08:22

Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion

Published on: March 20, 2017

8.8K

科学分野:

  • 生物化学
  • 薬理学について
  • 薬物投与システム

背景:

  • インスリンはグルコースの調節に不可欠なホルモンです.
  • 現在のインスリン製剤は,薬動学的プロファイルに制限があります.
  • インスリン機能の向上は,糖尿病治療の重要な目標です.

研究 の 目的:

  • 精密なインスリン改変のための新しいプラットフォームを導入します.
  • このプラットフォームがインスリン薬の機能性を改善する可能性を調査する.

主な方法:

  • インスリンのための標的型改変プラットフォームの開発.
  • 改変されたインスリン特性のインビトロおよびインビボ試験

主要な成果:

  • インスリン構造を正確に変化させる能力が示されています.
  • インスリンの安定性と活性性の改善が観察されました.
  • パーソナライズされた薬理学プロファイルの可能性

結論:

  • 精密なインスリン改変のプラットフォームが 期待されています
  • このアプローチは,インスリンベースの治療法の改善につながる可能性があります.
  • 臨床的な応用を探るため,さらなる研究が必要である.